Kolon TissueGene, Inc. (KOSDAQ:950160)

Market Cap	3.31T
Revenue	n/a
Net Income	n/a
Shares Out	81.60M
EPS	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	225,220
Average Volume	408,884
Open	40,650
Previous Close	40,600
Day's Range	39,700 - 41,625
52-Week Range	13,080 - 59,300
Beta	-0.80
RSI	56.11
Earnings Date	n/a

About Kolon TissueGene

Kolon TissueGene, Inc. develops cell therapies for orthopedic diseases and other unmet medical needs. The company’s lead product is the TG-C that has completed Phase II trials to treat osteoarthritis, as well as rheumatoid arthritis, meniscus, and spinal discs. It is also developing cell therapies for musculoskeletal system disorders, as well as vet medicine. Kolon TissueGene, Inc. was formerly known as TissueGene, Inc. and changed its name to Kolon TissueGene, Inc. in March 2018. The company was founded in 1999 and is headquartered in Rockvill...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 29
• Stock Exchange: KOSDAQ
• Ticker Symbol: 950160